Premier Biomedical Pain Management Solutions Executives Advance Plans For An Array Of Opioid-Free New Products To Compete In $112 Billion Global Pain Market Beginning January, 2017
Posted at November 9, 2016 | By : Admin | Categories : Investor News,News,Press Releases | 0 CommentEL PASO, TX – November 9, 2016 – Premier Biomedical, Inc. (OTCQB: BIEI) a biotech research public company focused on discovering, developing, and commercializing medical treatments for a wide range of diseases in humans, including innovative therapies for breast cancer as well as non-narcotic, all-natural-ingredient, 50-state legal, novel pain management therapies, announced today that the management team from their Pain Management Division will attend an upcoming cannabis business conference & expo, November 15-18, 2016 in Las Vegas. This conference is the longest running, most respected cannabis industry conference, bringing together over 7500 cannabis industry leaders and over 300 exhibitors in one place.
William A. Hartman, President and CEO of Premier Biomedical, stated, “This is a tremendous opportunity for us to get a better picture of this growing segment of the all-natural-ingredient pain management industry, from scouting the competition, to benchmarking competitive products and establishing key contacts with suppliers, distributors, and potential customers. The experience gathered at this conference will also assist us in our on-going efforts to launch products to compete in the $112 billion global pain management market. Our initial product sales are slated to begin in just a few weeks, in January, 2017, with continuing multiple product launches throughout 2017. The products we will be launching include a 96-hour pain patch versus the competition at 6-12 hours, roll-ons, creams, sprays, lip balms and capsules.”
Ronald T. LaBorde, Managing Director of Premier’s Pain Management Solutions Joint Venture, said, “This is the premier event in the cannabis industry. Every serious player in the industry from growers, to manufacturers, to investors, to distributors and customers attend this event – a veritable Who’s Who of the industry. This conference comes at exactly the right time for us, as we are in the process of launching our global manufacturing and marketing strategies for our products.”
About Premier Biomedical, Inc.
Premier Biomedical, Inc. (OTCQB: BIEI) is a research-based publicly traded company that intends to discover and develop medical treatments for a wide range of diseases in humans, focusing on two major areas – 1) Biologics and Extracorporeal Treatments; and 2) Non-narcotic Pain Management Products. Premier has obtained, via exclusive license agreements, the technology behind three granted US Patents, multiple pending patents and provisional patents, and a PCT Europe National Patent. Founded in 2010, Premier has partnered with the Department of Defense with Center of Expertise at the William Beaumont Army Medical Center and the University of Texas at El Paso (UTEP). The company’s R&D efforts are centered in El Paso, TX, and their business offices are in Western Pennsylvania. The Company is a fully-reporting issuer whose common stock trades on the OTCQB marketplace maintained by OTC Markets Group, Inc. under the ticker symbol “BIEI.” For more information please visit our website: http://www.premierbiomedical.com/.
Safe Harbor Notice
Certain statements contained herein are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.